research and clinical care center is launched by faculty experts
recruited as part of UB 2020
BUFFALO, N.Y. – The Food and Drug Administration’s approval last week of the first hepatitis C virus (HCV) treatments that cure patients without interferon is a dramatic, positive development, according to a University at Buffalo expert in liver disease.
The new therapies are oral medications and do not require interferon, a drug that is administered via injection and that has significant side effects. New treatments are likely to make liver transplants for HCV much less common, says Andrew H. Talal, MD, professor in the Department of Medicine in the UB School of Medicine and Biomedical Sciences.
In response to the changing therapeutic landscape, UBMD Internal
Medicine is launching a center for Clinical Care and Research in
Liver Disease, which Talal will direct. The center’s primary
objective will be to advance research, clinical management and
education on liver disease to lessen the burden of these diseases
in Western New York.
- See more at: http://www.buffalo.edu/news/releases/2014/10/016.html#sthash.0gKLLqnX.dpuf
Labels: research, Talal, University of Buffalo